Search
-
News
MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon and rectal cancer.
… Tuesday, March 21, 2017 Summary In this Q&A, MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon cancer and rectal cancer. Colorectal cancer is the third most common cancer in the United States for both men and women, excluding
-
Partnering Opportunities
Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration.
… Tuesday, December 17, 2024 Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration. The i-HD eSource Scale Up Task Force, led by the European Institute for Innovation through
-
News
Uterine-preserving surgery results in excellent and similar five-year disease-specific survival compared to hysterectomy in young women with stage IB1 cervical cancer.
… Monday, January 14, 2019 Uterine-preserving surgery results in excellent and similar five-year disease-specific survival compared to hysterectomy in young women with stage IB1 cervical cancer , especially in women with smaller tumors, according to our recent research. The retrospective study is one of
-
News
Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.
… Monday, May 11, 2020 Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite the challenges of Covid-19, according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S.
-
News
Our review summarizes recent developments in treatment planning and delivery, existing clinical evidence, and ongoing prospective trials in major head and neck cancers that may further increase the therapeutic window of proton therapy for patients with head and neck cancer.
… Tuesday, October 13, 2020 Proton beam radiation has distinct tissue-sparing advantages over conventional photon-based radiation, making it especially beneficial for treating localized head and neck cancers, which typically have complex anatomy and are located near vital organs. We recently published
-
News
MSK's Neil Iyengar will present at the American Association for Cancer Research special conference about the risk of invasive breast cancer. A new study found that the risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat. These findings suggest that having a normal BMI can provide false reassurance regarding the risk of breast cancer associated with body fat, and they also highlight the potential role of physical activity and exercise even in those who are at a normal weight. For expert interviews, please contact Nicole H. McNamara at [email protected].
… Friday, January 26, 2018 Bottom Line: The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer. In addition, a lower level of
-
News
Dr. Sawyers is recognized for his dedication to cancer research, education, collaboration, science policy, advocacy, and funding.
… Friday, April 9, 2021 Memorial Sloan Kettering (MSK) is proud to announce that Charles L. Sawyers, MD, FAACR , Chair of MSK’s Human Oncology and Pathogenesis Program (HOPP) and Howard Hughes Medical Institute Investigator, will receive the 2021 American Association for Cancer Research (AACR) Distinguished
-
News
Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.
… Wednesday, May 20, 2015 Memorial Sloan Kettering Cancer Center (MSK) today announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient
-
News
There is a clear and unmet need for less invasive and more accurate methods for diagnosing lung cancer. A promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK) is the electronic nose (e-nose), which evaluates volatile organic compounds (VOCs) in exhaled breath. The e-nose platform detects a lung cancer-associated “breathprint” in breath from individuals with lung cancer.
… Friday, September 15, 2023 There is a clear and unmet need for less invasive and more accurate methods for diagnosing lung cancer. A promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK) is the electronic nose (e-nose), which evaluates volatile organic compounds (VOCs
-
News
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
… Monday, February 22, 2021 Summary The level of genetic mutations in a tumor, called tumor mutational burden (TMB), has been used to predict how people with cancer will respond to immunotherapy. But MSK physician-scientist Luc Morris explains that important aspects of TMB’s clinical relevance have needed